5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) – Pipeline Review, H2 2016’, provides in depth analysis on 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted pipeline therapeutics.

The report provides comprehensive information on the 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)

The report reviews 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics and enlists all their major and minor projects

The report assesses 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Bristol-Myers Squibb Company

Corvus Pharmaceuticals Inc

Innate Pharma SA

MedImmune LLC

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC

3.1.3.5) Overview 6

Therapeutics Development 7

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC

3.1.3.5) - Products under Development by Stage of Development 7

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC

3.1.3.5) - Products under Development by Therapy Area 8

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC

3.1.3.5) - Products under Development by Indication 9

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC

3.1.3.5) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC

3.1.3.5) - Products under Development by Companies 12

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC

3.1.3.5) - Products under Development by Universities/Institutes 14

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC

3.1.3.5) - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 18

Assessment by Molecule Type 19

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC

3.1.3.5) - Companies Involved in Therapeutics Development 21

Bristol-Myers Squibb Company 21

Corvus Pharmaceuticals Inc 22

Innate Pharma SA 23

MedImmune LLC 24

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC

3.1.3.5) - Drug Profiles 25

Antibody to Inhibit CD73 for Oncology - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

BMS-986179 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

durvalumab + oleclumab - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Monoclonal Antibody to Inhibit CD73 for Cancer - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Monoclonal Antibody to Inhibit CD73 for Oncology - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Monoclonal Antibody to Inhibit CD73 for Oncology - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Monoclonal Antibody to Inhibit CD73 for Oncology - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

oleclumab - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Small Molecule to Inhibit CD73 for Oncology - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Small Molecules to Inhibit CD73 for Oncology - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC

3.1.3.5) - Dormant Projects 35

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC

3.1.3.5) - Featured News & Press Releases 36

Apr 18, 2016: Innate Pharma presents new CD73 checkpoint inhibitor program 36

Feb 24, 2014: CD73 Research Could Lead to Cancer Drug 36

Appendix 38

Methodology 38

Coverage 38

Secondary Research 38

Primary Research 38

Expert Panel Validation 38

Contact Us 38

Disclaimer 39

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 20

Pipeline by Bristol-Myers Squibb Company, H2 2016 21

Pipeline by Corvus Pharmaceuticals Inc, H2 2016 22

Pipeline by Innate Pharma SA, H2 2016 23

Pipeline by MedImmune LLC, H2 2016 24

Dormant Projects, H2 2016 35

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Molecule Types, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 19

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports